It will not prevent headaches or reduce the number of attacks.You should not use Imitrex if you have uncontrolled Also tell your doctor if you are taking an antidepressant such as citalopram (Celexa), desvenlafaxine (Pristiq), duloxetine (Cymbalta), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem), fluvoxamine (Luvox), paroxetine (Paxil), sertraline (Zoloft), or venlafaxine (Effexor).Imitrex will only treat a headache that has already begun. Objective: The objective of this article is to evaluate the efficacy and tolerability of two doses of oral sumatriptan vs placebo in the acute treatment of migraine in children and adolescents. Use the medicine exactly as directed.You may receive your first dose in a hospital or clinic setting to quickly treat any serious side effects.Read and carefully follow any Instructions for Use provided with your medicine.
Call your doctor if your symptoms do not improve after using this medicine.Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.Overdose symptoms may include tremors, skin redness in your arms or legs, weakness, loss of coordination, breathing problems, blue-colored lips or fingernails, vision problems, or a seizure (convulsions).Avoid driving or hazardous activity until you know how this medicine will affect you. Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks. This drug is not approved for use in children. If you log out, you will be required to enter your username and password the next time you visit. Sumatriptan is administered orally, subcutaneously, or intranasally.
For the treatment of migraine, if side effects are dose limiting, lower doses (1 mg to 5 mg) may be used The maximum cumulative dose that may be given in 24 hours is 12 mg, two 6-mg injections separated by at least 1 hour. 6 mg (0.5 mL) SC with autoinjector; may repeat in ≥1 hourMild to moderate hepatic impairment: Oral not to exceed 50 mg/dose; no dosage adjustments necessary if administered SC (use with caution)Use not recommended (higher incidence of adverse effects)MI and coronary artery vasospasm in patients with CAD risk factors (extremely rare)Current/history of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes (angina, MI, stroke, TIA, ischemic bowel disease)History of stroke, transient ischemic attack, or hemiplegic or basilar migraineHistory of coronary artery disease or coronary artery vasospasmWolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disordersWithin 24 hours of another 5-HT1 receptor agonist or ergot-type medicationsBefore treating headaches in patients not previously diagnosed with migraine or cluster headache or in patients who present with atypical symptoms, exclude other potentially serious neurological conditionsEqually effective at any stage of migraine, although early use recommendedOveruse of acute migraine drugs (eg, ergotamine, triptans, opioids, or combination of these drugs for ≥10 days/month) may lead to exacerbation of headache (medication overuse headache); detoxification may be necessaryBinds to melanin, may cause toxicity to melanin-rich tissues on prolonged useVery rare reports of transient and permanent blindness and significant partial vision lossSerotonin syndrome may occur, particularly during combined use with SSRIs (eg, fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram) or SNRIs (eg, venlafaxine, duloxetine); discontinue therapy if it occursCerebral/subarachnoid hemorrhage and stroke reported with 5-HT1 agonist administration; discontinue if it occursSignificant elevation of blood pressure, including hypertensive crisis, reportedNot for administration to patients with risk factors for coronary artery diseaseUse caution in patients with history of seizure disorder or lowered seizure thresholdMay cause depression including dizziness, weakness, or drowsiness (infrequent); caution when operating heavy machineryCoronary artery vasospasm, transient ischemia, ventricular tachycardia/fibrillation, myocardial infarction, cardiac arrest and death reported with use 5HT1 agonists; perform cardiac evaluation in patients with multiple cardiovascular risk factors; evaluate for coronary artery disease in patients at high risk; discontinue therapy if arrhythmia occursUse oral formulations with caution in patients with mild-to-moderate hepatic impairment if treatment necessary and advisable; presystemic clearance, when administered orally, is reduced in hepatic impairment and cause an increase in plasma concentrations; dose reduction recommended; when adminsitered parenterally (SC, intranasal), does not undergo first pass metabolism and may not cause increase in plasma concentrationsHypersensitivity reactions, including angioedema and anaphylaxis, reported; needle shield of prefilled syringe contains dry natural rubber (a latex derivative) that has potential to cause allergic reactions in latex-sensitive individualsData from a prospective pregnancy exposure registry and epidemiological studies of pregnant women have not detected increased frequency of birth defects or consistent pattern of birth defects among women exposed to sumatriptan compared with general population; in developmental toxicity studies in rats and rabbits, oral administration of sumatriptan to pregnant animals was associated with embryolethality, fetal abnormalities, and pup mortality; when administered by intravenous route to pregnant rabbits, sumatriptan was embryolethalHowever, possible disease-associated maternal and/or embryo/fetal risk reported; several studies have suggested that women with migraine may be at increased risk of preeclampsia during pregnancySumatriptan is excreted in human milk following subcutaneous administration; there are no data on effects of sumatriptan on breastfed infant or effects of sumatriptan on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for injection and any potential adverse effects on breastfed infant from sumatriptan or from underlying maternal conditionInfant exposure to sumatriptan can be minimized by avoiding breastfeeding for 12 hr after therapyA: Generally acceptable.
If your child has been given this drug, ask the doctor for information about the benefits and risks. Ask your doctor or pharmacist if you do not understand these instructions.After using Imitrex: If your headache does not completely go away, or goes away and comes back, use a second dose if it has been at least 2 hours since your first dose.Never use more than your recommended dose. For such patients, consider periodic cardiovascular evaluation in intermittent long-term users of Imitrex Injection.Life-threatening disturbances of cardiac rhythm, including ventricular tachycardia and ventricular fibrillation leading to death, have been reported within a few hours following the administration of 5-HTSensations of tightness, pain, pressure, and heaviness in the precordium, throat, neck, and jaw commonly occur after treatment with Imitrex Injection and are usually non-cardiac in origin. Dosage in children Forms used in children; Promethazine (Phenergan) 0.25 to 0.5 mg per kg per dose three times daily. Clinical data to determine the frequency of serious adverse reactions in pediatric patients who might receive subcutaneous, oral, or intranasal IMITREX are not presently available.Clinical trials of Imitrex Injection did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. and formulary information changes.
Available for Android and iOS devices. Additional smaller observational studies evaluating use of sumatriptan during pregnancy have not suggested an increased risk of teratogenicity.Oral administration of sumatriptan to rats prior to and throughout gestation resulted in embryofetal toxicity (decreased body weight, decreased ossification, increased incidence of skeletal abnormalities). In general, anaphylactic reactions to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens. A dangerous drug interaction could occur.
This information does not take the place of talking with your healthcare provider about your medical condition or treatment.
The recommended dose of IMITREX tablets is 25 mg, 50 mg, or 100 mg. Doses of 50 mg and 100 mg may provide a greater effect than the 25-mg dose, but doses of 100 mg may not provide a greater effect than the 50-mg dose. However, the doctor may decide the benefits of taking this drug outweigh the risks. Use only after a clear diagnosis of migraine has been established Oral: Initial dose: 25 mg, 50 mg, or 100 mg orally, once -If some response to first dose occurs, a second dose may be administered at least 2 hours after first dose if needed -Oral doses of 50 and 100 mg may provide greater relief than 25 mg; however, a 100 mg dose may not provide greater effect than a 50 mg dose Maximum dose: 200 mg per 24 hours Subcutaneous: Initial dose: 1 to 6 mg subcutaneous… 2002
Call your doctor if your symptoms do not improve after using this medicine.Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.Overdose symptoms may include tremors, skin redness in your arms or legs, weakness, loss of coordination, breathing problems, blue-colored lips or fingernails, vision problems, or a seizure (convulsions).Avoid driving or hazardous activity until you know how this medicine will affect you. Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks. This drug is not approved for use in children. If you log out, you will be required to enter your username and password the next time you visit. Sumatriptan is administered orally, subcutaneously, or intranasally.
For the treatment of migraine, if side effects are dose limiting, lower doses (1 mg to 5 mg) may be used The maximum cumulative dose that may be given in 24 hours is 12 mg, two 6-mg injections separated by at least 1 hour. 6 mg (0.5 mL) SC with autoinjector; may repeat in ≥1 hourMild to moderate hepatic impairment: Oral not to exceed 50 mg/dose; no dosage adjustments necessary if administered SC (use with caution)Use not recommended (higher incidence of adverse effects)MI and coronary artery vasospasm in patients with CAD risk factors (extremely rare)Current/history of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes (angina, MI, stroke, TIA, ischemic bowel disease)History of stroke, transient ischemic attack, or hemiplegic or basilar migraineHistory of coronary artery disease or coronary artery vasospasmWolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disordersWithin 24 hours of another 5-HT1 receptor agonist or ergot-type medicationsBefore treating headaches in patients not previously diagnosed with migraine or cluster headache or in patients who present with atypical symptoms, exclude other potentially serious neurological conditionsEqually effective at any stage of migraine, although early use recommendedOveruse of acute migraine drugs (eg, ergotamine, triptans, opioids, or combination of these drugs for ≥10 days/month) may lead to exacerbation of headache (medication overuse headache); detoxification may be necessaryBinds to melanin, may cause toxicity to melanin-rich tissues on prolonged useVery rare reports of transient and permanent blindness and significant partial vision lossSerotonin syndrome may occur, particularly during combined use with SSRIs (eg, fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram) or SNRIs (eg, venlafaxine, duloxetine); discontinue therapy if it occursCerebral/subarachnoid hemorrhage and stroke reported with 5-HT1 agonist administration; discontinue if it occursSignificant elevation of blood pressure, including hypertensive crisis, reportedNot for administration to patients with risk factors for coronary artery diseaseUse caution in patients with history of seizure disorder or lowered seizure thresholdMay cause depression including dizziness, weakness, or drowsiness (infrequent); caution when operating heavy machineryCoronary artery vasospasm, transient ischemia, ventricular tachycardia/fibrillation, myocardial infarction, cardiac arrest and death reported with use 5HT1 agonists; perform cardiac evaluation in patients with multiple cardiovascular risk factors; evaluate for coronary artery disease in patients at high risk; discontinue therapy if arrhythmia occursUse oral formulations with caution in patients with mild-to-moderate hepatic impairment if treatment necessary and advisable; presystemic clearance, when administered orally, is reduced in hepatic impairment and cause an increase in plasma concentrations; dose reduction recommended; when adminsitered parenterally (SC, intranasal), does not undergo first pass metabolism and may not cause increase in plasma concentrationsHypersensitivity reactions, including angioedema and anaphylaxis, reported; needle shield of prefilled syringe contains dry natural rubber (a latex derivative) that has potential to cause allergic reactions in latex-sensitive individualsData from a prospective pregnancy exposure registry and epidemiological studies of pregnant women have not detected increased frequency of birth defects or consistent pattern of birth defects among women exposed to sumatriptan compared with general population; in developmental toxicity studies in rats and rabbits, oral administration of sumatriptan to pregnant animals was associated with embryolethality, fetal abnormalities, and pup mortality; when administered by intravenous route to pregnant rabbits, sumatriptan was embryolethalHowever, possible disease-associated maternal and/or embryo/fetal risk reported; several studies have suggested that women with migraine may be at increased risk of preeclampsia during pregnancySumatriptan is excreted in human milk following subcutaneous administration; there are no data on effects of sumatriptan on breastfed infant or effects of sumatriptan on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for injection and any potential adverse effects on breastfed infant from sumatriptan or from underlying maternal conditionInfant exposure to sumatriptan can be minimized by avoiding breastfeeding for 12 hr after therapyA: Generally acceptable.
If your child has been given this drug, ask the doctor for information about the benefits and risks. Ask your doctor or pharmacist if you do not understand these instructions.After using Imitrex: If your headache does not completely go away, or goes away and comes back, use a second dose if it has been at least 2 hours since your first dose.Never use more than your recommended dose. For such patients, consider periodic cardiovascular evaluation in intermittent long-term users of Imitrex Injection.Life-threatening disturbances of cardiac rhythm, including ventricular tachycardia and ventricular fibrillation leading to death, have been reported within a few hours following the administration of 5-HTSensations of tightness, pain, pressure, and heaviness in the precordium, throat, neck, and jaw commonly occur after treatment with Imitrex Injection and are usually non-cardiac in origin. Dosage in children Forms used in children; Promethazine (Phenergan) 0.25 to 0.5 mg per kg per dose three times daily. Clinical data to determine the frequency of serious adverse reactions in pediatric patients who might receive subcutaneous, oral, or intranasal IMITREX are not presently available.Clinical trials of Imitrex Injection did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. and formulary information changes.
Available for Android and iOS devices. Additional smaller observational studies evaluating use of sumatriptan during pregnancy have not suggested an increased risk of teratogenicity.Oral administration of sumatriptan to rats prior to and throughout gestation resulted in embryofetal toxicity (decreased body weight, decreased ossification, increased incidence of skeletal abnormalities). In general, anaphylactic reactions to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens. A dangerous drug interaction could occur.
This information does not take the place of talking with your healthcare provider about your medical condition or treatment.
The recommended dose of IMITREX tablets is 25 mg, 50 mg, or 100 mg. Doses of 50 mg and 100 mg may provide a greater effect than the 25-mg dose, but doses of 100 mg may not provide a greater effect than the 50-mg dose. However, the doctor may decide the benefits of taking this drug outweigh the risks. Use only after a clear diagnosis of migraine has been established Oral: Initial dose: 25 mg, 50 mg, or 100 mg orally, once -If some response to first dose occurs, a second dose may be administered at least 2 hours after first dose if needed -Oral doses of 50 and 100 mg may provide greater relief than 25 mg; however, a 100 mg dose may not provide greater effect than a 50 mg dose Maximum dose: 200 mg per 24 hours Subcutaneous: Initial dose: 1 to 6 mg subcutaneous… 2002